Brian M Alexander
Overview
Explore the profile of Brian M Alexander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
158
Citations
6035
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rendo V, Lee E, Bossi C, Khuu N, Rudek M, Pal S, et al.
Sci Transl Med
. 2025 Feb;
17(786):eadn6274.
PMID: 39970230
Inhibitors of murine double minute homolog 2 (MDM2) represent a promising therapeutic approach for the treatment of wild-type glioblastomas (GBMs), reactivating p53 signaling to induce cancer cell death. We conducted...
2.
Lee E, Alexander B, Romo C, Supko J, Agar N, Talebi Z, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39820282
Purpose: Adavosertib is an oral small molecular inhibitor of Wee1. The Adult Brain Tumor Consortium performed a phase I study of adavosertib, radiation (RT) and temozolomide (TMZ) in newly diagnosed...
3.
Rendo V, Lee E, Bossi C, Khuu N, Rudek M, Pal S, et al.
medRxiv
. 2024 Aug;
PMID: 39211865
Statement Of Significance: Tissue sampling during this clinical trial allowed us to assess mechanisms of response and resistance associated with navtemadlin treatment in recurrent GBM. We report that clinically achievable...
4.
Rahman R, Trippa L, Lee E, Arrillaga-Romany I, Fell G, Touat M, et al.
J Clin Oncol
. 2023 Sep;
41(36):5524-5535.
PMID: 37722087
Purpose: The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial that uses response adaptive randomization and genomic profiling to efficiently identify novel therapies for...
5.
Heilmann A, Riess J, McLaughlin-Drubin M, Huang R, Hjulstrom M, Creeden J, et al.
Oncologist
. 2023 Sep;
29(2):e224-e236.
PMID: 37682776
Background: FoundationOneCDx is approved in the US and Japan as a companion diagnostic test to identify patients with cancer who may benefit from treatment with 30 drug therapies in the...
6.
Haberberger J, Pegram W, Britt N, Schiavone K, Severson E, Sharaf R, et al.
Oncologist
. 2023 Aug;
29(1):e47-e58.
PMID: 37619245
The authors present a cohort of 661 young adult glioblastomas diagnosed using 2016 WHO World Health Organization Classification of Tumors of the Central Nervous System, utilizing comprehensive genomic profiling (CGP)...
7.
Rahman R, Ventz S, Redd R, Cloughesy T, Alexander B, Wen P, et al.
Clin Cancer Res
. 2023 Mar;
29(12):2194-2198.
PMID: 36939557
Drug development can be associated with slow timelines, particularly for rare or difficult-to-treat solid tumors such as glioblastoma. The use of external data in the design and analysis of trials...
8.
Avalos-Pacheco A, Ventz S, Arfe A, Alexander B, Rahman R, Wen P, et al.
JCO Precis Oncol
. 2023 Feb;
7:e2200606.
PMID: 36848613
Purpose: Adaptive clinical trials use algorithms to predict, during the study, patient outcomes and final study results. These predictions trigger interim decisions, such as early discontinuation of the trial, and...
9.
Blandin A, Giglio R, Graham M, Garcia G, Malinowski S, Woods J, et al.
Clin Cancer Res
. 2023 Feb;
29(14):2651-2667.
PMID: 36780194
Purpose: Anaplastic lymphoma kinase (ALK) aberrations have been identified in pediatric-type infant gliomas, but their occurrence across age groups, functional effects, and treatment response has not been broadly established. Experimental...
10.
Dean J, Tanguturi S, Cagney D, Shin K, Youssef G, Aizer A, et al.
Neuro Oncol
. 2022 Nov;
25(6):1100-1112.
PMID: 36402744
Background: Glioblastomas comprise heterogeneous cell populations with dynamic, bidirectional plasticity between treatment-resistant stem-like and treatment-sensitive differentiated states, with treatment influencing this process. However, current treatment protocols do not account for...